Why the Biggest Barrier in Genomics Isn’t the Science: A Conversation with Andrea Riposati of Dante Omics
Whole genome sequencing is cheaper than ever, yet fewer than 20% of oncology patients get sequenced. Andrea Riposati of Dante Omics explains why.
From Compound Microarray to a Global Drug Discovery CRO: A Conversation with Haiching Ma of Reaction Biology
We sat down with founder and CSO Haiching Ma to talk about how the
company got its start, how it has scaled through acquisition, where AI genuinely is
(and isn’t) changing drug discovery today, and what he thinks Reaction Biology needs
to become over the next 25 years.
From Proteomic Discovery to the Clinic: A Conversation with Steve Williams from Alamar Biosciences
Steve Williams, CSO of Alamar Biosciences, on proteomics, precision medicine, multidimensional diagnostics, and bridging the gap between biomarker discovery and clinical care.
From Biologics to Gene Therapy: A Conversation with Jim McNally
Jim McNally, CSO of Sword Bio, on gene therapy, CRO partnerships, multi-omics, and the rising complexity of modern bioanalytical drug development.
From Plasma Proteomics to Spatial Interactomics: A Conversation with Simon Fredriksson
The field of proteomics has long lived in the shadow of the genomic revolution, primarily due to the technical challenges of analyzing proteins at scale.
Carolina Molecular Named Certified Sequencing Service Provider by Alamar Biosciences
MORRISVILLE, N.C. — Carolina Molecular (“CMI”), a premier molecular testing laboratory and NGS foundry, today announced it has been named a certified sequencing service provider by Alamar Biosciences.
Carolina Molecular Brings AVITI™ Sequencing to the Southeast
Carolina Molecular is now the only certified AVITI™ service provider in the Southeast, having integrated Element Biosciences’ AVITI System into our NGS Foundry.
The Evolution of Precision Medicine: A Conversation with Tom Turi from Flagship Biosciences
The transition from descriptive biology to quantitative precision medicine has been more than a technological evolution; it has been a complete paradigm shift in how we identify targets and treat patients.
Carolina Molecular Partners with Pixelgen, Becomes First US Certified Service Provider for Pixelgen Proxiome Kit
Collaboration expands access to scalable, cost-efficient single-cell RNA sequencing for translational and clinical research
Carolina Molecular Selected as Certified Service Provider for CS Genetics’ Single-Cell Sequencing Platform
Collaboration expands access to scalable, cost-efficient single-cell RNA sequencing for translational and clinical research